Phathom Pharmaceuticals (PHAT) Enterprise Value
Price: $5.01
Market Cap: $348.53M
Avg Volume: 1.20M
Market Cap: $348.53M
Avg Volume: 1.20M
Country: US
Industry: Biotechnology
Sector: Healthcare
Industry: Biotechnology
Sector: Healthcare
Enterprise Value Summary (Quarterly)
According to Phathom Pharmaceuticals's latest quarterly financial reports:
- The enterprise value (EV) is 481.53M, which includes the market capitalization, debt, and subtracts cash and cash equivalents. EV provides a more comprehensive measure of a company's total value.
- The market capitalization is 512.99M, which is calculated by multiplying the current share price by the total number of outstanding shares.
- The stock price is $8.12, with 71.04M shares outstanding.
- The company has 297.26M in cash and cash equivalents and 201.91M in total debt.
Enterprise Value (EV) Formula:
EV = Market Cap + Total Debt - Cash and Cash Equivalents
Enterprise value is often used instead of market cap because it provides a more accurate valuation of a company by including debt and subtracting cash, giving a fuller picture of the company's total value.
Enterprise Value
$481.53M
Market Cap
$576.88M
Total Debt
$201.91M
Cash and Equivalents
$297.26M
Historical Enterprise Value
Phathom Pharmaceuticals Historical Enterprise Values
The table below shows various enterprise value metrics for each quarter, with the latest data available for 2024-12-31.
| Date | Enterprise Value | EV Change (%) | Stock Price | Number of Shares | Market Cap | Cash & Equivalents | Total Debt |
|---|---|---|---|---|---|---|---|
| December 31, 2024 | $481.53M | -52.33% | $8.12 | 71.04M | $576.88M | $297.26M | $201.91M |
| September 30, 2024 | $1.01B | 17.04% | $18.08 | 64.63M | $1.17B | $334.68M | $176.41M |
| June 30, 2024 | $863.15M | 12.75% | $10.81 | 58.56M | $633.01M | $276.24M | $506.38M |
| March 31, 2024 | $765.56M | 172.70% | $10.6 | 58.37M | $618.74M | $322.23M | $469.05M |
| December 31, 2023 | $280.73M | -40.99% | $9.13 | 57.29M | $523.10M | $381.39M | $139.03M |
| September 30, 2023 | $475.76M | -12.70% | $10.37 | 56.78M | $588.83M | $213.68M | $100.61M |
| June 30, 2023 | $544.99M | 101.01% | $14.32 | 48.50M | $694.53M | $248.85M | $99.31M |
| March 31, 2023 | $271.13M | -33.09% | $7.14 | 42.35M | $302.41M | $129.57M | $98.30M |
| December 31, 2022 | $405.19M | 23.12% | $11.22 | 41.31M | $463.51M | $155.38M | $97.07M |
| September 30, 2022 | $329.10M | 56.66% | $11.08 | 38.82M | $430.13M | $196.84M | $95.81M |
| June 30, 2022 | $210.08M | -55.51% | $8.44 | 38.27M | $323.02M | $207.39M | $94.45M |
| March 31, 2022 | $472.20M | -27.44% | $13.61 | 38.04M | $517.68M | $138.09M | $92.61M |
| December 31, 2021 | $650.78M | -38.76% | $19.67 | 37.76M | $742.70M | $183.26M | $91.34M |
| September 30, 2021 | $1.06B | -1.60% | $32.1 | 37.30M | $1.20B | $224.62M | $90.07M |
| June 30, 2021 | $1.08B | -8.06% | $33.85 | 36.64M | $1.24B | $209.67M | $49.54M |
| March 31, 2021 | $1.17B | 31.55% | $37.56 | 36.30M | $1.36B | $237.97M | $49.30M |
| December 31, 2020 | $893.00M | -14.62% | $33.22 | 34.06M | $1.13B | $287.50M | $49.02M |
| September 30, 2020 | $1.05B | 17.90% | $36.67 | 33.37M | $1.22B | $226.36M | $48.69M |
| June 30, 2020 | $887.08M | 41.17% | $32.91 | 33.00M | $1.09B | $247.27M | $48.42M |
| March 31, 2020 | $628.38M | -20.55% | $25.82 | 32.47M | $838.39M | $256.67M | $46.67M |
| December 31, 2019 | $790.94M | 30.42% | $31.14 | 32.47M | $1.01B | $243.76M | $23.57M |
| September 30, 2019 | $606.46M | 149.26% | $24.6 | 22.89M | $563.10M | $74.48M | $117.84M |
| June 30, 2019 | $243.30M | 14.82% | $24.6 | 8.58M | $211.03M | $82.92M | $115.19M |
| March 31, 2019 | $211.91M | -0.09% | $24.6 | 8.58M | $211.03M | $-879.00K | $- |
| December 31, 2018 | $212.10M | 0.51% | $24.6 | 8.58M | $211.03M | $879.00K | $1.95M |
| September 30, 2018 | $211.03M | 60.90% | $24.6 | 8.58M | $211.03M | $- | $- |
| June 30, 2018 | $131.15M | 0.00% | $24.6 | 5.33M | $131.15M | $- | $- |
| March 31, 2018 | $131.15M | - | $24.6 | 5.33M | $131.15M | $- | $- |
Related Metrics
Explore detailed financial metrics and analysis for PHAT.